Oncolytics Biotech (ONCY) Stock
Clinical stage biotech developing viral cancer treatment. Here's the price, business snapshot, and what's worth knowing about Oncolytics Biotech in June 2026.
Oncolytics Biotech Inc (ONCY) is a clinical-stage biotechnology company developing pelareorep (also known as REOLYSIN), a reovirus-based oncolytic immunotherapy intended to selectively infect and kill tumour cells and stimulate anti-tumour immune responses. The company is focused on combination studies pairing pelareorep with chemotherapy, immune checkpoint inhibitors and other agents across multiple solid tumour indications. With a market capitalisation around $108.12M, Oncolytics is a small-cap, research-driven business with typical biotech dynamics: value is largely tied to clinical trial readouts, regulatory progress and partnerships. Investors should expect high volatility, potential dilution from financing, and long development timelines. While the mechanism has scientific rationale and some encouraging early data, outcomes are uncertain. This summary is for general educational purposes only and is not investment advice; investors should consider their risk tolerance and seek personalised financial guidance before making decisions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Oncolytics Biotech's stock with a target price of $3.57, indicating potential growth.
Financial Health
Oncolytics Biotech is generating modest profits and cash flow, indicating stable but limited financial growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ONCY
Precision Oncology Stocks: Could This Theme Gain Momentum?
Revolution Medicines recently reported stellar Phase 3 trial results for its pancreatic cancer drug, sending its stock soaring and validating novel targeted therapies. This breakthrough creates a compelling investment opportunity across the broader oncology sector, particularly for biotechnology firms specializing in genetic mutations and precision medicine.
Published: 14 April 2026
Explore BasketPrecision Oncology RAS Inhibitor Stocks to Watch 2026
Former Senator Ben Sasse recently spotlighted Revolution Medicines' upcoming Phase 3 trial results for a new pancreatic cancer pill. This high-profile endorsement brings broader market attention to biotech companies developing innovative therapies for historically untreatable, RAS-dependent solid tumors.
Published: 12 April 2026
Explore BasketPharma Buyouts Explained | Healthcare M&A Analysis
Merck's decision to end its acquisition talks with Revolution Medicines highlights the high-stakes environment for biotech M&A. This failed deal could signal an opportunity for other pharmaceutical giants to acquire promising oncology assets, creating a ripple effect across the sector.
Published: 26 January 2026
Explore BasketAlternative Cancer Therapies Focus Shifts 2025
The FDA's new boxed warning for Johnson & Johnson and Legend Biotech's cancer drug highlights potential safety issues in CAR-T therapies. This could shift focus to companies developing alternative and potentially safer oncology treatments.
Published: 13 October 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: 11 July 2025
Explore BasketWhy You’ll Want to Watch This Stock
Clinical-stage immunotherapy
Pelareorep aims to both kill tumour cells and boost anti-tumour immunity; trial readouts can materially affect prospects, though results are uncertain.
Combination therapy focus
Many studies pair pelareorep with chemo or immune checkpoint inhibitors — partnerships could de‑risk development but regulatory hurdles remain.
Speculative small-cap
Market cap near $108M implies higher volatility and potential dilution; suitable for investors who accept biotech-specific risks and long timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
